Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus teriflunomide in relapsing multiple sclerosis with long-term remibrutinib extension
NL-OMON60273Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of remibrutinib in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate of confirmed relapses. Started Jun 2023; status: completed.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON60273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60273.